Plus Therapeutics Stock Investor Sentiment
| PSTV Stock | USD 1.29 0.01 0.78% |
Slightly above 65% of all Plus Therapeutics' sophisticated investors are looking to take a long position. The analysis of the overall investor sentiment regarding Plus Therapeutics suggests that some traders are interested. Plus Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Plus Therapeutics' earnings reports, geopolitical events, and overall market trends.
Plus |
Plus Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Plus Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Far too much social signal, news, headlines, and media speculation about Plus Therapeutics that are available to investors today. That information is available publicly through Plus media outlets and privately through word of mouth or via Plus internal channels. However, regardless of the origin, that massive amount of Plus data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Plus Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Plus Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Plus Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Plus Therapeutics alpha.
Plus Therapeutics Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Acquisition by Andrew Sims of 4098 shares of Plus Therapeutics at 1.27 subject to Rule 16b-3 | 09/10/2024 |
2 | Acquisition by Hedrick Marc H of 197595 shares of Plus Therapeutics at 1.26 subject to Rule 16b-3 | 09/11/2024 |
3 | Acquisition by Hawkins Richard J of 6285 shares of Plus Therapeutics at 1.3543 subject to Rule 16b-3 | 09/12/2024 |
4 | Acquisition by Hawkins Richard J of 4000 shares of Plus Therapeutics at 1.499 subject to Rule 16b-3 | 09/13/2024 |
5 | Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update at the 2024 Congress of Neurological Surgeons Annual Meeting | 10/01/2024 |
6 | Acquisition by Clowes Howard of 3000 shares of Plus Therapeutics at 2.42 subject to Rule 16b-3 | 10/10/2024 |
7 | Plus Therapeutics to Announce Third Quarter Financial Results and Host Conference Call on November 14, 2024 | 11/05/2024 |
8 | Organogenesis Tops Q3 Earnings and Revenue Estimates | 11/12/2024 |
9 | Plus Therapeutics GAAP EPS of -0.37 beats by 0.19, revenue of 1.45M beats by 0.31M | 11/14/2024 |
10 | What is HC Wainwrights Estimate for PSTV FY2028 Earnings | 11/20/2024 |
11 | Plus Therapeutics to Present Multi-Institutional Experience Using the CNSide Cerebrospinal Fluid Assay in Patients with Leptomeningeal Metastases | 11/21/2024 |
12 | Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Leptomeningeal ... | 11/25/2024 |
13 | Stem Cell Therapy Strategic Business Report 2024 - Allogeneic Stem Cell Therapy Segment is Expected to Reach US1 Billion by 2030 with a CAGR of a 16.7 | 12/02/2024 |
Additional Tools for Plus Stock Analysis
When running Plus Therapeutics' price analysis, check to measure Plus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Plus Therapeutics is operating at the current time. Most of Plus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Plus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Plus Therapeutics' price. Additionally, you may evaluate how the addition of Plus Therapeutics to your portfolios can decrease your overall portfolio volatility.